015A Stock Chart & Stats
€3.14
€0.00(0.00%)
At close: 4:00 PM EST
€3.14
€0.00(0.00%)
Day’s Range― - ―
52-Week Range€3.14 - €3.30
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€54.69M
Enterprise Value€84.94
Total Cash (Recent Filing)€4.45M
Total Debt (Recent Filing)€4.92M
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding85,539,030
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio0.01
Price to Book (P/B)1.74
Price to Sales (P/S)0.00
P/FCF Ratio-1.52
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€5.21Price Target Upside65.97% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Focused Clinical-Stage PipelineA narrow, disease-focused clinical-stage model concentrates resources on IPF, increasing expertise and program clarity. That specialization supports deeper scientific know-how, clearer regulatory pathways, and makes the company an attractive partner or acquisition target for larger players seeking pulmonary assets.
Modest Financial LeverageLow absolute debt relative to equity reduces near-term insolvency risk and preserves flexibility for structured financings or collaborations. Modest leverage means interest obligations are limited, allowing scarce cash to be allocated to R&D and trial execution rather than debt service.
Strengthened Near-Term Funding RunwayA sizeable equity raise and authorization to issue more shares extend operational runway into 2028, enabling completion of key clinical milestones. Secured near-term funding materially lowers immediate bankruptcy risk and supports continued trial progress without urgent asset sales.
Bears Say
No Revenue And Large Net LossesSustained lack of product revenue plus sizable recurring losses mean the company relies entirely on external financing. Over the medium term this raises execution risk: repeated capital raises can dilute shareholders and the company remains economically dependent on trial success or partner deals to become self-sustaining.
Negative Operating And Free Cash FlowPersistent negative operating and free cash flow indicate ongoing cash burn to fund R&D and operations. Even with improvement, continued negative FCF requires external capital; this structural cash dependency constrains strategic optionality and increases vulnerability to market or financing disruptions.
Equity Shrinkage And Dilution RiskAuthorized-share expansion combined with past sharp declines in equity signals higher dilution risk as the company likely issues shares to fund operations. Repeated dilution erodes per-share economics, can deter long-term investors, and reduces existing shareholders' upside if trial outcomes are delayed or uncertain.
Rein Therapeutics News
015A FAQ
What was Rein Therapeutics’s price range in the past 12 months?
Rein Therapeutics lowest stock price was €3.14 and its highest was €3.30 in the past 12 months.
What is Rein Therapeutics’s market cap?
Rein Therapeutics’s market cap is €54.69M.
When is Rein Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Rein Therapeutics’s earnings last quarter?
Currently, no data Available
Is Rein Therapeutics overvalued?
According to Wall Street analysts Rein Therapeutics’s price is currently Undervalued.
Does Rein Therapeutics pay dividends?
Rein Therapeutics does not currently pay dividends.
What is Rein Therapeutics’s EPS estimate?
Rein Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Rein Therapeutics have?
Rein Therapeutics has 85,539,030 shares outstanding.
What happened to Rein Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Rein Therapeutics?
Currently, no hedge funds are holding shares in DE:015A
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rein Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€5.21 (65.97% Upside)
€5.21 (65.97% Upside)
Insider Transactions
Bought Shares
Worth €64.4K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Negative
20 days / 200 days
Momentum
-18.85%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-54.38%
Trailing 12-Months
Company Description
Rein Therapeutics
Rein Therapeutics Inc. operates as a clinical-stage biopharmaceutical enterprise focused on discovering and bringing to market novel therapeutic solutions for various conditions, notably cancer. The company's leading drug candidate, ALRN-6924, is a distinctive cell-penetrating peptide. This compound works by disrupting the harmful interaction between the p53 suppressor proteins, MDM2 and MDMX, and the vital p53 tumor suppressor. Its goal is to reactivate the natural tumor-suppressing pathways in cancers where the p53 gene is still functional, or "wild-type." The organization was founded on August 6, 2001, by Gregory L. Verdine, Rosana Kapeller, Huw M. Nash, Joseph A. Yanchik III, and Loren David Walensky, and its main corporate offices are situated in Austin, Texas.
015A Stock 12 Month Forecast
Average Price Target
€5.21
▲(65.97% Upside)
Technical Analysis
Oncolytics Biotech
―
―
Cardiff Oncology
―
XBiotech
―
Elicio Therapeutics
―
Xilio Therapeutics
―